Insulet Corporation $PODD Shares Sold by State of New Jersey Common Pension Fund D

Key Points

• The State of New Jersey Common Pension Fund D reduced its stake in Insulet Corporation by 7.3% in Q1, now holding 23,565 shares valued at approximately $6.19 million.
• In recent analyst reports, ratings for Insulet have predominantly been positive, with 17 analysts rating it as a buy and a price target of around $330.71.
• Insulet reported a 32.9% increase in revenue year-over-year, generating $649.10 million and surpassing consensus estimates by $36.79 million.

State of New Jersey Common Pension Fund D reduced its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 7.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,565 shares of the medical instruments supplier's stock after selling 1,869 shares during the period. State of New Jersey Common Pension Fund D's holdings in Insulet were worth $6,188,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its stake in shares of Insulet by 55.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock worth $1,376,000 after buying an additional 1,867 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Insulet by 85.1% in the 1st quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock worth $236,000 after buying an additional 412 shares during the last quarter. QRG Capital Management Inc. boosted its stake in shares of Insulet by 75.6% in the 1st quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier's stock worth $533,000 after buying an additional 874 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in Insulet by 225.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock worth $408,000 after purchasing an additional 1,075 shares during the period. Finally, State of Alaska Department of Revenue raised its holdings in Insulet by 2.6% in the 1st quarter. State of Alaska Department of Revenue now owns 8,212 shares of the medical instruments supplier's stock worth $2,156,000 after purchasing an additional 210 shares during the period.

Insulet Price Performance

Shares of Insulet stock traded up $2.92 during trading on Friday, reaching $330.77. 499,504 shares of the stock traded hands, compared to its average volume of 705,185. The company has a market capitalization of $23.28 billion, a price-to-earnings ratio of 100.54, a P/E/G ratio of 2.75 and a beta of 1.35. The business has a fifty day simple moving average of $300.94 and a two-hundred day simple moving average of $285.90. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet Corporation has a 52-week low of $180.31 and a 52-week high of $334.18.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping the consensus estimate of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm's revenue was up 32.9% on a year-over-year basis. During the same quarter last year, the business posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on PODD shares. Royal Bank Of Canada raised their target price on Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Canaccord Genuity Group raised their price target on Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a report on Friday, August 8th. Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a report on Friday, May 16th. The Goldman Sachs Group assumed coverage on Insulet in a report on Friday, May 30th. They set a "buy" rating and a $380.00 price target on the stock. Finally, Oppenheimer raised their price target on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Sixteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Insulet has a consensus rating of "Moderate Buy" and a consensus price target of $332.71.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.